المؤلفون: V. Matveyev B., S. Tkachev I., M. Volkova I., A. Mitin A., V. Shelepova M., В. Матвеев Б., С. Ткачев И., М. Волкова И., А. Митин А., В. Шелепова М.

المصدر: Cancer Urology; Том 4, № 4 (2008); 38-44 ; Онкоурология; Том 4, № 4 (2008); 38-44 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2008-4-4

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1032/919; Kirby R. Management of clinically localized prostate cancer by radical prostatectomy followed by watchful waiting. Nat Clin Pract Urol 2005;2(6):298—303.; Lepor H., Nieder A.M., Ferrandino M.N. Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. J Urol 2001;166(5):1729—33.; Heinzer H., Hammerer P., Graefen M. et al. Thromboembolic complication rate after radical retropubic prostatectomy. Impact of routine ultrasonography for the detection of pelvic lymphoceles and hematomas. Eur Urol 1998;33(1):86—90.; Pepper R.J., Pati J., Kaisary A.V. The incidence and treatment of lymphoceles after radical retropubic prostatectomy. BJU Int 2005;95(6):772—5.; Solberg A., Angelsen A., Bergan U. et al. Frequency of lymphoceles after open and laparoscopic pelvic lymph node dissection in patients with prostate cancer. Scand J Urol Nephrol 2003;37(3):218—21.; Partin A.W., Mangold L.A., Lamm D.M. et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843—8.; Roberts W.W., Bergstralh E.J., Blute M.L. et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001;57:1033—7.; King C.R. Patterns of prostate cancer biopsy grading trends and clinical implications. Int J Cancer 2000;90:305—11.; Miyake H., Kurahashi T., Takenaka A. et al. Improved accuracy for predicting the gleason score of prostate cancer by increasing the number of transrectal biopsy cores. Urol Int 2007;79:302—6.; Hsu C.Y., Joniau S., Oyen R. et al. Detection of clinical unilateral T3a prostate cancer — by digital rectal examination or transrectal ultrasonography? BJU Int 2006;98(5):982—5.; Potosky A.L., Legler J., Albertsen P.C. et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate Cancer outcomes study. J Nat Cancer Inst 2000;92(19):1582—92.; Madalinska J.B., Essink-Bot M.L., de Koning H.J. et al. Quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001;19(6):1619—28.; Bianco F.J., Grignon D.J., Sakr W.A. et al. Radical prostatectomy with bladder neck preservation: impact of a positive margin. Eur Urol 2003;43(5):461—6.; Selli C., De Antoni P., Moro U. et al. Role of bladder neck preservation in urinary continence following radical retropubic prostatectomy. Scand J Urol Nephrol 2004;38(1):32—7.; Nandipati K.C., Raina R., Agarwal A. et al. Nerve-sparing surgery significantly affects long-term continence after radical prostatectomy. Urology 2007;70(6):1127—30.; Wagner A.A., Link R.E., Trock B.J. et al. Comparison of open and laparoscopic radical prostatectomy outcomes from a surgeon's early experience. Urology 2007;70(4):667—71.; Kundu S.D., Roehl K.A., Eggener S.E. et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004;172(6):2227—31.; Alibhai S.M., Leach M., Warde P.R. Major early complications after radical radiotherapy (RT) among 8,615 men: impact of age, comorbidity, and time. Proc ASCO 2005;abstr 98.; Claudio J. et al. Survival after radical prostatectomy and radiotherapy: a population-based study of 17,570 men. AUA 2007;abstr 380.; Kattan M.W., Wheeler T.M., Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17(5):1499.; https://oncourology.abvpress.ru/oncur/article/view/1032

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1032
https://doi.org/10.17650/1726-9776-2008-4-4-38-44

المؤلفون: Yu. Alyaev G., A. Vinarov Z., V. Shelepova M., Yu. Demidko L., Ю. Аляев Г., А. Винаров З., В. Шелепова М., Ю. Демидко Л.

المصدر: Cancer Urology; Том 5, № 3 (2009); 48-52 ; Онкоурология; Том 5, № 3 (2009); 48-52 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2009-5-3

مصطلحات موضوعية: disseminated prostate cancer, bone involvement, bisphosphonates, Zometa, диссеминированный рак предстательной железы, костные осложнения, бисфосфонаты, Зомета

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/262/279; Оха У.К., Логью Дж. Рак простаты. М.: Рид Элсивер, 2009.; Мазо Е.Б., Григорьев М.Э., Конорев В.А. Диагностическая и прогностическая ценность маркеров костного метаболизма в мониторинге больных раком предстательной железы, получающих гормональную терапию. В сб.: Материалы 2-го Конгресса РООУ. М., 2007.; Беневоленская Л.И. Бисфосфонаты и остеопороз. В кн.: Руководство по остеопорозу. Под ред. Л.И. Беневоленской. М.: БИНОМ. Лаборатория знаний, 2003.; Russell R.G., Croucher P.I., Rogers M.J. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9(Suppl 2): 66—80.; Кушлинский Н.Е., Любимова Н.В. Бисфосфонаты в лечении метастазов рака предстательной железы в кости. В кн.: Рак предстательной железы. Под ред. Н.Е. Кушлинского, Ю.Н. Соловьева, М.Ф. Трапезниковой. М.: РАМН, 2002.; Body J.J., Lortholary A., Romieu G. et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14(9):1557—61.; Lipton A., Theriault R.L., Hortobagyi G.N. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88(5):1082—90.; Migliorati C.A., Siegel M.A., Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7(6):508—14.; Матвеев Б.П., Карякин О.Б., Матвеев В.Б. и др. Зомета в лечении больных распространенным раком предстательной железы (результаты Российского многоцентрового исследования). Совр онкол 2004;6(3).; Hillner B.E., Ingle J.N., Chlebowski R.T. et al. Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21(21):4042—57.; Brown J.E., Cook R.J., Major P. et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97(1): 59—69.; Kyle R.A. Yee G.C., Somerfield M.R. et al. Clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25(17): 2464—72.; Герасимов А.Н. Медицинская статистика. М.: МИА, 2007.; https://oncourology.abvpress.ru/oncur/article/view/262

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/262
https://doi.org/10.17650/1726-9776-2009-5-3-48-52